{"entity":{"id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","aka":[],"tldr":"A phase 2 trial of GR1014-CG 2.4% in advanced solid tumours, run by Graegis Pharmaceuticals Ltd, active and no longer recruiting.","summary":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer is a phase 2 interventional study registered as NCT07192588 by Graegis Pharmaceuticals Ltd, with 273 participants enrolled, started 2024-07-26 and due to reach its primary completion in 2026-09-30. Interventions recorded: GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy and GR1014-CG 4.7%.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07192588","url":"https://clinicaltrials.gov/study/NCT07192588"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07192588","phase":"2","setting":"A Randomised, Double-Blind, Vehicle-Controlled, Multi-Centre, Parallel-Group Study to Investigate the Safety, Tolerability, and Efficacy of GR1014 Cutaneous Gel as a Topical Radioprotector in the Prevention of the Radiodermatitis Occurring With Adjuvant Radiotherapy for Localised Breast Cancer After Lumpectomy","sponsor":"Graegis Pharmaceuticals Ltd","enrolled":273,"outcomes":[]},"route":"/trials/nct07192588/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}